Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT02039258
A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 295
- Registration Number
- NCT02034162
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 77
- Registration Number
- NCT02034344
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 218
- Registration Number
- NCT02025907
A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 559
- Registration Number
- NCT02019472
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 59
- Registration Number
- NCT02009488
A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT02008279
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT02000700
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 108
- Registration Number
- NCT01998958
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 240
- Registration Number
- NCT01998971
© Copyright 2024. All Rights Reserved by MedPath